Please login to the form below

Not currently logged in
Email:
Password:

HER3 inhibitors

This page shows the latest HER3 inhibitors news and features for those working in and with pharma, biotech and healthcare.

Daiichi pulls study of patritumab in lung cancer

Daiichi pulls study of patritumab in lung cancer

Other companies working on HER3 inhibitors include Merrimack Pharma, whose seribantumab (MM-121) candidate is in phase III, as well as GlaxoSmithKline with GKS2849330 (phase I) and Roche's Genentech unit ... which has a dual HER3/EGFR inhibitor called

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....